DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 148 filers reported holding DENALI THERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is 0.39 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,015,144 | -41.8% | 34,400 | -54.6% | 0.00% | -40.0% |
| Q1 2023 | $1,745,073 | -15.7% | 75,741 | +1.8% | 0.01% | -16.7% |
| Q4 2022 | $2,070,037 | -74.2% | 74,435 | -71.5% | 0.01% | -77.8% |
| Q3 2022 | $8,015,000 | +323.4% | 261,170 | +306.0% | 0.03% | +350.0% |
| Q2 2022 | $1,893,000 | +96.2% | 64,324 | +114.4% | 0.01% | +100.0% |
| Q1 2022 | $965,000 | +152.6% | 30,001 | +249.8% | 0.00% | +200.0% |
| Q4 2021 | $382,000 | -93.3% | 8,576 | -92.5% | 0.00% | -92.3% |
| Q3 2021 | $5,735,000 | -66.7% | 113,671 | -48.2% | 0.01% | -66.7% |
| Q2 2021 | $17,211,000 | -39.3% | 219,415 | -55.8% | 0.04% | -47.3% |
| Q1 2021 | $28,362,000 | +29.7% | 496,703 | +90.3% | 0.07% | +17.5% |
| Q4 2020 | $21,867,000 | +219.5% | 261,070 | +36.7% | 0.06% | +162.5% |
| Q3 2020 | $6,845,000 | +125.5% | 191,045 | +52.2% | 0.02% | +60.0% |
| Q2 2020 | $3,036,000 | – | 125,538 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 5,960,732 | $122,969,901 | 14.32% |
| ARCH Venture Management, LLC | 693,749 | $14,312,042 | 9.30% |
| Flagship Pioneering Inc. | 2,619,968 | $54,049,940 | 3.92% |
| Casdin Capital, LLC | 1,300,000 | $26,819,000 | 2.97% |
| Yiheng Capital Management, L.P. | 1,150,684 | $23,738,611 | 1.21% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 154,000 | $3,172,400 | 1.07% |
| SECTORAL ASSET MANAGEMENT INC | 254,941 | $5,259,433 | 1.02% |
| Temasek Holdings (Private) Ltd | 6,895,992 | $142,264,315 | 0.85% |
| Clarius Group, LLC | 378,262 | $7,803,545 | 0.74% |
| Artal Group S.A. | 802,899 | $16,564 | 0.71% |